webleads-tracker

Pharma Compliance Info Undisclosed conflicts of interest among biomedical textbook authors US Sunshine Act

Undisclosed conflicts of interest among biomedical textbook authors

Textbooks are a formative resource for health care providers during their education and are also an enduring reference for pathophysiology and treatment. Unlike the primary literature and clinical guidelines, biomedical textbook authors do not typically disclose potential financial conflicts of interest (pCoIs). The objective of this study was to evaluate whether the authors of textbooks used in the training of physicians, pharmacists, and dentists had appreciable undisclosed pCoIs in the form of patents or compensation received from pharmaceutical or biotechnology companies
Authors were listed as inventors on 677 patents (maximum/author = 23), with three-quarters (74.9%) to HarPIM authors. Females were significantly underrepresented among patent holders.Pharma Compliance Info Undisclosed conflicts of interest among biomedical textbook authors US Sunshine Act
The PDD 2009–2013 database revealed receipt of US$13.2 million, the majority to (83.9%) to HarPIM. The maximum compensation per author was $869,413. The PDD 2014 database identified receipt of $6.8 million, with 50.4% of eligible authors receiving compensation. The maximum compensation received by a single author was $560,021. Cardiovascular authors were most likely to have a PDD entry and neurologic disorders authors were least likely.
Conclusion: An appreciable subset of biomedical authors have patents and have received remuneration from medical product companies and this information is not disclosed to readers. These findings indicate that full transparency of financial pCoI should become a standard practice among the authors of biomedical educational materials.

To read the full article

Check Also

Pharma Compliance Info The biopharmaceutical's stock took a tumble after the Wall Street Journal asserted that the company has been breaking the Sunshine Act US Sunshine Act

The biopharmaceutical’s stock took a tumble after the Wall Street Journal asserted that the company has been breaking the Sunshine Act

Shares of MiMedx Group (NASDAQ:MDXG), a biopharmaceutical company focused on regenerative medicine, were down 11% …

X